Zydus Lifesciences LimitedNSE: ZYDUSLIFE

Press Release Aug 31 2023

· Issued by Zydus Lifesciences Limited

Filed with NSE · · 2 pages · English

Summary by 6ix AI

Zydus Lifesciences Limited has issued a press release announcing that it received final approval from the USFDA for Isotretinoin Capsules in various strengths. The capsules are intended for the treatment of severe cystic acne that has not responded to other treatments. The drug will be manufactured at Zydus' facility in Moraiya, Ahmedabad.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Release

Zydus Lifesciences Limited has informed the Exchange regarding a press release dated August 31, 2023, titled "Zydus receives final approval from the USFDA for Isotretinoin Capsules USP, 10 mg, 20 mg 30 mg and 40 mg".

Zydus Lifesciences Limited on 6ix

Earlier from Zydus Lifesciences

Later from Zydus Lifesciences

All Zydus Lifesciences news releases